The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACRV | -75.13% | N/A | N/A | -88% |
| S&P | +19.89% | +109.18% | +15.89% | +71% |
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of drug pipeline. Its AP3 is used to generate proprietary OncoSignature companion diagnostics to identify the patients who will benefit from the medicines. The company was founded by Peter Blume-Jensen and Kristina Masson on March 03, 2018 and is headquartered in Watertown, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.30M | -50.0% |
| Market Cap | $37.31M | -79.2% |
| Market Cap / Employee | $0.48M | 0.0% |
| Employees | 78 | 34.5% |
| Net Income | -$21.01M | -11.7% |
| EBITDA | -$22.35M | -5.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $41.90M | -8.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.12M | -34.8% |
| Short Term Debt | $1.15M | 17.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.18% | -8.8% |
| Return On Invested Capital | -92.85% | 12.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17.10M | -21.8% |
| Operating Free Cash Flow | -$16.61M | -19.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.00 | 0.95 | 0.36 | 0.23 | -80.87% |
| Price to Tangible Book Value | 1.00 | 0.95 | 0.36 | 0.23 | -80.87% |
| Enterprise Value to EBITDA | -3.35 | -2.21 | 3.20 | 3.96 | -352.59% |
| Return on Equity | -46.0% | -54.1% | -62.4% | -47.9% | 26.71% |
| Total Debt | $4.01M | $3.65M | $3.51M | $3.26M | -22.70% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
